8-K current report · filed Nov 4, 2026

Cullinan Therapeutics, Inc. (CGEM) 8-K Current Report: November 4, 2026

Item 7.01Item 8.01Item EX-99.1CGEM overview

Short answer

Cullinan Therapeutics, Inc. (CGEM) filed an 8-K current report with the SEC on November 4, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Updated CLN-049 Phase 1 dose-escalation data planned for December ASH meeting.

Cullinan Therapeutics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 7.01 · Regulation FD Disclosure

  • Updated CLN-049 Phase 1 dose-escalation data planned for December ASH meeting
  • Data concern relapsed or refractory AML and MDS patients
  • Presentation may provide investors new evidence on CLN-049’s clinical activity and development prospects

Item 8.01 · Other Events

  • Phase 1 CLN-049 data in 87 relapsed/refractory AML or MDS patients support advancing the program into ongoing Phase 2 testing
  • Two-step dosing reduced CRS to 26% from 36%, with only Grade 1 or Grade 2 events
  • At 12 µg/kg, CRc reached 21% and ORR 45%; lower starting step-up dosing improved CRc to 26% and ORR 53%
  • Key Grade 3+ adverse events: febrile neutropenia 18%, transaminase elevations 14%, pneumonia 12%
  • Five patients achieved MRD-negative responses, while four used CLN-049 as a bridge to stem cell transplantation

Item EX-99.1 · Exhibit EX-99.1

  • ASH presentations on December 12-15 feature updated CLN-049 Phase 1 AML/MDS data and four total posters across oncology and autoimmune programs
  • CLN-049 reports anti-leukemic activity at selected Phase 2 target doses of 6 µg/kg and 12 µg/kg
  • Double step-up dosing showed a favorable safety profile, supporting progression toward Phase 2 regimens
  • CLN-049 expansion into newly diagnosed AML combines with azacitidine and venetoclax, potentially broadening its treatment opportunity
  • Velinotamig advances into Phase 1b/2a trials for immune thrombocytopenia and warm autoimmune hemolytic anemia, with new preclinical BCMA selectivity data

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Cullinan Therapeutics, Inc. 8-K filings

Get the next CGEM 8-K as it lands

Follow CGEM for push alerts, or ask the research agent what this filing means.